Skip to main content

Research Repository

Advanced Search

In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line Thumbnail


Abstract

The antiretroviral drug efavirenz displays many desirable pharmacokinetic properties such as a long half-life enabling once daily dosing but suffers from central nervous system safety issues. Various nanotechnologies have been explored to mitigate some of the limitations with efavirenz. While there has been progress in increasing the bioavailability, there has been no attempt to assess the impact of increased exposure to efavirenz on central nervous system safety. The uptake of aqueous and solid drug nanoparticle (SDN) formulations of efavirenz was assessed in the human cerebral microvessel endothelial cells/D3 brain endothelial cell line. The mechanisms of uptake were probed using a panel of transport and endocytosis inhibitors. The cellular accumulation of an efavirenz aqueous solution was significantly reduced by amantadine, but this was not observed with SDNs. The uptake of efavirenz SDNs was reduced by dynasore, but concentrations of the efavirenz aqueous solution were not affected. These data indicate that efavirenz is a substrate for transporters in brain endothelial cells (amantadine is an inhibitor of organic cation transporters 1 and 2), and formation of SDNs may bypass this interaction in favour of a mechanism involving dynamin-mediated endocytosis.

Acceptance Date Aug 10, 2017
Publication Date Oct 2, 2017
Publicly Available Date Mar 28, 2024
Journal Journal of Interdisciplinary Nanomedicine
Print ISSN 2058-3273
Pages 157-169
DOI https://doi.org/10.1002/jin2.32
Keywords blood brain barrier, central nervous system, Efavirenz, Endocytosis, solid drug nanoparticle
Publisher URL http://doi.org/10.1002/jin2.32

Files





Downloadable Citations